Analyzing immune system issues in patients
SYSTEMS-LEVEL ANALYSES OF IMMUNE DYSREGULATION
This study is trying to collect blood and stool samples from people with immune system problems and healthy individuals to better understand these issues and help improve treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Sex | All |
| Sponsor | Karolinska Institutet Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Stockholm) |
| Trial ID | NCT06248957 on ClinicalTrials.gov |
What this trial studies
This study aims to create a national resource in Sweden for comprehensive immunological analyses of individuals with various forms of immune system dysregulation. It will establish a biobank of blood and fecal samples from patients with confirmed or suspected immune dysregulation, as well as healthy controls for comparison. The project will also develop a national database containing deep immunological data, treatment outcomes, and clinical information, accessible to researchers and clinicians involved in the study.
Who should consider this trial
Good fit: Ideal candidates include individuals of all ages with suspected immune dysregulation or known immune-mediated diseases who have not responded to standard therapies.
Not a fit: Patients who are healthy controls with any diagnosis of an immune-mediated disorder or currently undergoing immunomodulatory treatment will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and treatment options for patients with immune dysregulation.
How similar studies have performed: Other studies have shown success in analyzing immune dysregulation, but this approach of creating a comprehensive national resource is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients of all ages seeking care or being referred for suspected immune dysregulation or with a known immune-mediated disease and failing to respond to standard therapy Exclusion Criteria: Healthy control individuals will be excluded on the basis of having a diagnosis of an immune mediated disorder, immunomodulatory treatment or current infection or cancer.
Where this trial is running
Stockholm
- Karolinska Institutet — Stockholm, Sweden (Recruiting)
Study contacts
- Study coordinator: Petter Brodin, M.D., Ph.D
- Email: petter.brodin@ki.se
- Phone: 08 524 813 96
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.